Neil Josephson Biography and Net Worth

Insider of Zymeworks

Dr. Josephson joined Zymeworks in April 2019 and currently serves as our interim Chief Medical Officer and Senior Vice President, Clinical Research. Prior to joining Zymeworks he was a Vice President in Clinical Development at Seattle Genetics where he worked on multiple early and late-stage programs from 2013-2019, including leading the first line approval of ADCETRIS^® in Hodgkin Lymphoma. From 2002-2013 Dr. Josephson was a full-time faculty member of the Division of Hematology at the University of Washington and the Puget Sound Blood Center, serving as an Associate Professor of Medicine and the Director of Hemophilia Care Program. He completed fellowship training in Hematology and Oncology at the University of Washington and holds an M.D. degree from Columbia University and an A.B. in biology from Dartmouth College.

What is Neil Josephson's net worth?: The estimated net worth of Neil Josephson is at least $341.43 thousand as of November 10th, 2022. Dr. Josephson owns 14,449 shares of Zymeworks stock worth more than $341,430 as of February 24th. This net worth estimate does not reflect any other assets that Dr. Josephson may own. Learn More about Neil Josephson's net worth.
How do I contact Neil Josephson?: The corporate mailing address for Dr. Josephson and other Zymeworks executives is 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on Neil Josephson's contact information.
Has Neil Josephson been buying or selling shares of Zymeworks?: Neil Josephson has not been actively trading shares of Zymeworks during the past quarter. Most recently, Neil Josephson sold 2,475 shares of the business's stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $8.10, for a transaction totalling $20,047.50. Following the completion of the sale, the insider now directly owns 14,449 shares of the company's stock, valued at $117,036.90. Learn More on Neil Josephson's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Kenneth Galbraith (Chair & CEO), Mark Hollywood (COO), Neil Josephson (Insider), Neil Klompas (CFO), Paul Moore (Chief Scientific Officer), Kathryn O'Driscoll (Insider), James Priour (Insider), Jeffrey Smith (Executive Vice President and Chief Medical Officer), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last year, Zymeworks insiders bought shares 13 times. They purchased a total of 1,405,768 shares worth more than $16,773,032.28. During the last year, insiders at the sold shares 8 times. They sold a total of 187,933 shares worth more than $4,673,716.04. The most recent insider tranaction occured on January, 12th when CEO Kenneth Galbraith sold 30,424 shares worth more than $689,712.08. Insiders at Zymeworks own 33.5% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/12/2026.

Neil Josephson Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/10/2022	Sell	2,475	$8.10	$20,047.50	14,449
1/7/2022	Buy	5,000	$14.28	$71,400.00

Neil Josephson Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Today's Range

Now: $23.63

$22.80

$23.68

50 Day Range

MA: $24.19

$22.02

$27.62

2 Week Range

Now: $23.63

$9.03

$28.49

Volume

445,321 shs

Average Volume

777,076 shs

Market Capitalization

$1.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25